Loading
A phase 3 trial of Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., active and no longer recruiting.
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer is a phase 3 interventional study registered as NCT06016738 by Olema Pharmaceuticals, Inc., with 510 participants enrolled, started 2023-11-16 and due to reach its primary completion in 2026-10-31. Interventions recorded: Palazestrant, Fulvestrant, Anastrozole, Letrozole and Exemestane.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Olema Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Exemestane, Fulvestrant and the tag pipeline.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Exemestane, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Exemestane, Fulvestrant and the tag pipeline.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/